Keywords: teva, sales, full-year, reach, billion, copaxone, forges
Teva sales for full-year 2000 reach $1.75 billion as Copaxone forges ahead
Article | 16 February 2001
Israel's largest drugmaker, Teva Pharmaceutical Industries, hasreported net income (before one-time charges) of $57.9 million for the fourth quarter of 2000, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
